SCSeung Ha Cha

Seung Ha Cha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seung Ha Cha has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer

    by Ki Choon Sim, Min Ju Kim, Deuk Jae Sung, Beom Jin Park, Na Yeon Han, Yeo Eun Han, Seung Ha Cha

    Bladder cancer is a common malignancy with high recurrence rates and significant morbidity, necessitating accurate diagnostic and prognostic tools. Although cystoscopy and transurethral resection of bladder tumor (TURBT) remain reference standards, these approaches are invasive and limited by sampling errors and understaging. Consequently, there is growing interest in non-invasive biomarkers, including urine-based assays, blood-based markers, and imaging-derived parameters. Among these biomarkers, multiparametric magnetic resonance imaging (mpMRI), particularly with the Vesical Imaging Reporting and Data System (VI-RADS), has emerged as a robust non-invasive imaging biomarker for local staging and risk stratification. Recent evidence suggests that mpMRI plays a role in predicting treatment response and recurrence, particularly in the context of neoadjuvant therapy. This review provides a comprehensive overview of current non-invasive diagnostic and prognostic biomarkers in bladder cancer, with a particular emphasis on imaging biomarkers. We discuss their clinical utility, limitations, and future integration into multimodal decision-making frameworks.


  • Open Access

    Assessing Image Quality in Multiplexed Sensitivity-Encoding Diffusion-Weighted Imaging with Deep Learning-Based Reconstruction in Bladder MRI

    by Seung Ha Cha, Yeo Eun Han, Na Yeon Han, Min Ju Kim, Beom Jin Park, Ki Choon Sim, Deuk Jae Sung, Seulki Yoo, Patricia Lan, Arnaud Guidon

    Background/Objectives: This study compared the image quality of conventional multiplexed sensitivity-encoding diffusion-weighted imaging (MUSE-DWI) and deep learning MUSE-DWI with that of vendor-specific deep learning (DL) reconstruction applied to bladder MRI. Methods: This retrospective study included 57 patients with a visible bladder mass. DWI images were reconstructed using a vendor-provided DL algorithm (AIRTM Recon DL; GE Healthcare)—a CNN-based algorithm that reduces noise and enhances image quality—applied here as a prototype for MUSE-DWI. Two radiologists independently assessed qualitative features using a 4-point scale. For the quantitative analysis, signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), signal intensity ratio (SIR), and apparent diffusion coefficient (ADC) of the bladder lesions were recorded by two radiologists. The weighted kappa test and intraclass correlation were used to evaluate the interobserver agreement in the qualitative and quantitative analyses, respectively. Wilcoxon signed-rank test was used to compare the image quality of the two sequences. Results: DL MUSE-DWI demonstrated significantly improved qualitative image quality, with superior sharpness and lesion conspicuity. There were no significant differences in the distortion or artifacts. The qualitative analysis of the images by the two radiologists was in good to excellent agreement (κ ≥ 0.61). Quantitative analysis revealed higher SNR, CNR, and SIR in DL MUSE-DWI than in MUSE-DWI. The ADC values were significantly higher in DL MUSE-DWI. Interobserver agreement was poor (ICC ≤ 0.32) for SNR and CNR and excellent (ICC ≥ 0.85) for SIR and ADC values in both DL MUSE-DWI and MUSE-DWI. Conclusions: DL MUSE-DWI significantly enhanced the image quality in terms of lesion sharpness, conspicuity, SNR, CNR, and SIR, making it a promising tool for clinical imaging.


  • Development and validation of CT‑based radiomics model of PET-negative residual CT masses: a potential biomarker for predicting relapse‑free survival in non-Hodgkin lymphoma patients showing complete metabolic response

    by Seung Ha Cha, Ka-Won Kang, Na Yeon Han, Yongwon Cho, Deuk Jae Sung, Beom Jin Park, Min Ju Kim, Ki Choon Sim, Yeo Eun Han, Hwa Jung Sung

    Purpose PET-negative residual CT masses (PnRCMs) are usually dismissed as nonviable post-treatment lesions in non-Hodgkin lymphoma (NHL) patients showing complete metabolic response (CMR). We aimed to develop and validate computed tomography (CT)-based radiomics model of PET-negative residual CT mass (PnRCM) for predicting relapse-free survival (RFS) in NHL patients showing CMR. Methods A total of 224 patients who showed CMR after completing first-line chemotherapy for PET-avid NHL were recruited for model development. Patients with PnRCM were selected in accordance with the Lugano classification. Three-dimensional segmentation was done by two readers. Radiomic scores (RS) were constructed using features extracted using the Least-absolute shrinkage and selection operator analysis among radiomics features of PnRCMs showing more than substantial interobserver agreement (> 0.6). Cox regression analysis was performed with clinical and radiologic features. The performance of the model was evaluated using area under the curve (AUC). For validation, 153 patients from an outside hospital were recruited and analyzed in the same way. Results In the model development cohort, 68 (30.4%) patients had PnRCM. Kaplan–Meier analysis showed that patients with PnRCM had significantly (p = 0.005) shorter RFS than those without PnRCM. In Kaplan–Meier analysis, the high RS group showed significantly (p = 0.038) shorter RFS than the low-scoring group. Multivariate Cox regression analysis showed that high IPI score [hazard ratio (HR) 2.46; p = 0.02], treatment without rituximab (HR 3.821; p = 0.019) were factors associated with shorter RFS. In estimating RFS, combined model in both development and validation cohort showed AUC values of 0.81. Conclusion The combined model that incorporated both clinical parameters and CT-based RS showed good performance in predicting relapse in NHL patients with PnRCM. Graphical abstract